Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Pozycja w akcjach #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Cena akcji
$50.82
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$102.09M
Zmiana (1 dzień)
1.90%
Zmiana (1 rok)
-
Kraj
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategoria

Historia ceny akcji dla Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Najwyższa cena zamknięcia: $50.63 dnia 2026-08-01

Najniższa cena zamknięcia: $27.02 dnia 2026-05-01
Historia cen akcji firmy Hemab Therapeutics Holdings, Inc. Common Stock od 2026 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
Za mało danych dla podanych dat.
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH